# Bioadhesive Buccal Discs of Fluvastatin Sodium

A thesis submitted in the partial fulfillment of the requirements for the Master degree of Pharmaceutical Sciences (Pharmaceutics)

By

### Nada Abdulla Saleh Assaedi

Bachelor degree of Pharmacy and Biotechnology, 2008 German University in Cairo

Under the Supervision of

### Prof. Dr. Nagia Nagib Afifi

Professor of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy, Cairo University and German University in Cairo

### Prof. Dr. Gehanne Abdel Samie Awad

Professor of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy, Ain Shams University

Ain Shams University
Faculty of Pharmacy
Department of Pharmaceutics and Industrial Pharmacy
2016

# Bioadhesive Buccal Discs of Fluvastatin Sodium

### Acknowledgement

First and foremost, thanks to Allah for helping and guiding me to fulfill this work.

I want to express my profound appreciation and sincere gratitude to my supervisor Prof. Dr. Nagia Nagib Afifi, professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University and German University in Cairo, for her supervision, valuable guidance, and the continuous support and great patience throughout the development of this work.

I would also like to express my thanks and gratitude to Prof. Dr. Gehanne Abdel Samie Awad, professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, for her great academic assistance to accomplish this work.

I would like to truly thank Prof. Dr. Ahmed Hassan Elshafeey and all staff members of the Genuine Research Center, Cairo, Egypt, for their kind assistance and excellent support in the in-vivo study on human volunteers.

I would like to thank the staff members of the Pharmaceutics and Industrial Pharmacy department, Faculty of Pharmacy, Ain Shams University.

Words are not enough to express my deepest thanks and gratitude to my dear parents for their continuous guidance, endless support and encouragement that helped me get through the difficulties faced while accomplishing this work. I dedicate this work to them.

Finally, a special debt of gratitude is acknowledged to my dear husband and two beloved sons for putting up with me and supporting me throughout this journey.

## **Dedication**

This work is dedicated to my dearest parents,

Abdulla and Huda Assaedi, with love.

### **List of Contents**

| Item  | Page |
|---|------|
| List of Contents  | I    |
| List of Abbreviations   | III  |
| List of Tables  | V    |
| List of Figures   | VIII |
| Abstract  | XI   |
| <b>General Introduction</b>                                   | 1    |
| The oral mucosa   | 2    |
| Drug absorption   | 5    |
| Mucoadhesion  | 9    |
| Buccal drug delivery systems                                  | 16   |
| Fluvastatin sodium  | 23   |
| Scope of Work   | 27   |
| Chapter I: Formulation and Evaluation of Bioadhesive Buccal   |      |
| Discs of Fluvastatin Sodium                                   |      |
| 1. Introduction   | 29   |
| 2. Experimental   | 38   |
| 2.1. Materials  | 38   |
| 2.2. Equipment  | 38   |
| 2.3. Methodology  | 39   |
| 2.3.1. Spectrophotometric determination of fluvastatin sodium | 39   |
| 2.3.2. Preparation of bioadhesive buccal discs                | 39   |
| 2.3.3. Release study  | 40   |
| 2.3.4. Permeation study                                       | 42   |
| 2.3.5. Bioadhesion study                                      | 44   |
| 2.3.6. Evaluation of physicochemical characteristics          | 46   |

| Item   | Page |
|--|------|
| 2.3.7. Effect of aging   | 48   |
| 2.3.8. Statistical analysis  | 49   |
| 3. Results and Discussion  | 50   |
| 4. Conclusions   | 88   |
| Chapter II: In-Vivo Relative Bioavailability of the Selected Bioadhesive Buccal Disc Formulation |      |
| 1. Introduction  | 90   |
| 2. Experimental  | 93   |
| 2.1. Materials   | 93   |
| 2.2. Equipment   | 94   |
| 2.3. Methodology   | 94   |
| 2.3.1. Study design  | 94   |
| 2.3.2. Liquid chromatography-mass spectrometry (LC-MS/MS)  | 95   |
| 2.3.3. Pharmacokinetic analysis  | 97   |
| 2.3.4. Statistical analysis  | 98   |
| 2.3.5. Ex-vivo/in-vivo correlation   | 98   |
| 3. Results and Discussion  | 100  |
| 4. Conclusions   | 109  |
| Summary  | 110  |
| References   | 116  |
| Arabic Summary   |      |

### **List of Abbreviations**

| AE       | Adverse events                          |
|----------|---|
| API      | Active pharmaceutical ingredient        |
| AUC      | Area under the curve                    |
| CD       | Cyclodextrin                            |
| CET      | Cetrimide                               |
| CHD      | Coronary heart disease                  |
| СР       | Carbopol                                |
| CR       | Controlled release                      |
| DMSO     | Dimethyl sulfoxide                      |
| EC       | Ethyl cellulose                         |
| ER       | Extended release                        |
| FRA      | Fraction absorbed                       |
| FRP      | Fraction permeated                      |
| FVS      | Fluvastatin sodium                      |
| GG       | Guar gum                                |
| HDL      | High density lipoproteins               |
| HMG-CoA  | 3-hydroxy-3-methyl glutaryl coenzyme A  |
| HPMC     | Hydroxypropylmethyl cellulose           |
| НР-β-СО  | Hydroxypropyl-beta-cyclodextrin         |
| HVD      | Half value duration                     |
| IR       | Immediate release                       |
| LC-MS/MS | Liquid chromatography-mass spectrometry |
| LDL      | Low density lipoproteins                |
| MCC      | Microcrystalline cellulose              |
| MCGs     | Membrane coating granules               |
| MRT      | Mean residence time                     |

| OA   | Oleic acid                     |
|------|--------------------------------|
| PEG  | Polyethylene glycol            |
| RH   | Relative humidity              |
| SALG | Sodium alginate                |
| SCMC | Sodium carboxymethyl cellulose |
| SC   | Sodium cholate                 |
| SDC  | Sodium deoxycholate            |
| SLS  | Sodium lauryl sulfate          |
| SR   | Sustained release              |
| T80  | Tween 80                       |

### **List of Tables**

| Table | Table Name   | Page |
|-------|--|------|
| No.   |  |      |
| i     | Characteristics of the oral mucosa.                        | 4    |
| ii    | List of permeation enhancers.                              | 8    |
| iii   | List of some of the drugs investigated for buccal          | 18   |
|       | mucoadhesive tablets.                                      |      |
| iv    | List of some of the drugs investigated for buccal          | 19   |
|       | mucoadhesive discs.  |      |
| V     | Commercially available buccal adhesive formulations.       | 22   |
| 1     | Composition of bilayered buccoadhesive discs.              | 41   |
| 2.1   | Relation between absorbance and concentration of           | 51   |
|       | fluvastatin sodium at 303 nm in phosphate buffer pH 6.8.   |      |
| 2.2   | Relation between absorbance and concentration of           | 51   |
|       | fluvastatin sodium at 303 nm in phosphate buffer saline of |      |
|       | pH 7.4.  |      |
| 3.1   | In-vitro release of fluvastatin sodium from buccal discs   | 62   |
|       | containing single polymers and release enhancers.          |      |
| 3.2   | In-vitro release of fluvastatin sodium from buccal discs   | 63   |
|       | containing HPMC polymer blends and release enhancers.      |      |
| 4     | Permeation data of selected fluvastatin sodium             | 68   |
|       | buccoadhesive disc formulations.                           |      |
| 5     | Permeation of fluvastatin sodium from buccoadhesive        | 74   |
|       | disc formulation (F10) using different permeation          |      |
|       | enhancers.   |      |
| 6     | Composition of modified formulations containing (4%)       | 75   |
|       | sodium deoxycholate as permeation enhancer.                |      |

| Table | Table Name  | Page |
|-------|---|------|
| No.   |   |      |
| 7     | Permeation data of modified fluvastatin sodium              | 77   |
|       | buccoadhesive disc formulations containing 4% sodium        |      |
|       | deoxycholate as permeation enhancer.                        |      |
| 8     | Bioadhesion parameters of fluvastatin sodium buccal         | 79   |
|       | discs.  |      |
| 9     | In-vitro release data of fluvastatin sodium from            | 80   |
|       | buccoadhesive discs (F27).                                  |      |
| 10    | Kinetic parameters of F27 release data according to         | 82   |
|       | Korsmeyer-Peppas model.                                     |      |
| 11    | Physical characteristics of fluvastatin sodium              | 84   |
|       | buccoadhesive discs (F27).                                  |      |
| 12    | Swelling data of fluvastatin sodium buccoadhesive discs     | 84   |
|       | (F27).  |      |
| 13.1  | Effect of storage at ambient conditions for the selected    | 86   |
|       | formula (F27).  |      |
| 13.2  | Effect of storage at accelerated conditions of 40°C and     | 86   |
|       | 75% RH for the selected formula (F27).                      |      |
| 14    | Effect of storage at ambient and accelerated conditions for | 87   |
|       | drug release.   |      |
| 15    | Peak area ratio of LC-MS/MS analysis data using             | 100  |
|       | fluvastatin sodium (Analyte) and atorvastatin calcium (IS)  |      |
|       | in plasma.  |      |
| 16.1  | Plasma concentration – time data of fluvastatin sodium      | 104  |
|       | following the application of the test formula (F27)         |      |
|       | bioadhesive buccal discs to six volunteers.                 |      |

| Table<br>No. | Table Name  | Page |
|--------------|---|------|
| 16.2         | Plasma concentration – time data of fluvastatin sodium    | 104  |
|              | following the application of the reference formula        |      |
|              | (Lescol®) peroral capsules to six volunteers.             |      |
| 17.1         | Pharmacokinetic parameters of fluvastatin sodium          | 105  |
|              | following the application of the test formula (F27)       |      |
|              | bioadhesive buccal discs.                                 |      |
| 17.2         | Pharmacokinetic parameters of fluvastatin sodium          | 105  |
|              | following the application of the reference formula        |      |
|              | (Lescol®) peroral capsules.                               |      |
| 18           | Mean pharmacokinetic parameters of fluvastatin sodium     | 107  |
|              | after peroral and buccal administration.                  |      |
| 19           | Fraction of fluvastatin sodium permeated (ex-vivo) versus | 108  |
|              | fraction absorbed (in-vivo).                              |      |